

FIRST REGULAR SESSION  
HOUSE COMMITTEE SUBSTITUTE FOR  
**HOUSE BILL NOS. 593 & 695**  
**97TH GENERAL ASSEMBLY**

1605H.04C

D. ADAM CRUMBLISS, Chief Clerk

---

---

**AN ACT**

To amend chapter 338, RSMo, by adding thereto one new section relating to the Missouri oral chemotherapy parity interim committee.

---

---

*Be it enacted by the General Assembly of the state of Missouri, as follows:*

Section A. Chapter 338, RSMo, is amended by adding thereto one new section, to be  
2 known as section 338.321, to read as follows:

**338.321. 1. The “Missouri Oral Chemotherapy Parity Interim Committee” is**  
2 **hereby created to study the disparity in patient co-payments between orally and**  
3 **intravenously administered chemotherapies, the reasons for the disparity, and the patient**  
4 **benefits in establishing co-payment parity between oral and infused chemotherapy agents.**  
5 **The committee shall consider information on the costs or actuarial analysis associated with**  
6 **the delivery of patient oncology treatments. The conclusions of this study shall satisfy any**  
7 **statutorily required actuarial analysis.**

8 **2. The Missouri oral chemotherapy parity interim committee shall consist of the**  
9 **following members:**

10 **(1) Two members of the senate, appointed by the president pro tempore of the**  
11 **senate;**

12 **(2) Two members of the house of representatives, appointed by the speaker of the**  
13 **house of representatives;**

14 **(3) One member who is an oncologist or physician with expertise in the practice of**  
15 **oncology licensed in this state under chapter 334;**

16 **(4) One member who is an oncology nurse licensed in this state under chapter 335;**

17 **(5) One member who is a representative of a Missouri pharmacy benefit**  
18 **management company;**

EXPLANATION — Matter enclosed in bold-faced brackets [thus] in the above bill is not enacted and is intended to be omitted from the law. Matter in **bold-face** type in the above bill is proposed language.

19           **(6) One member from an organization representing licensed pharmacists in this**  
20 **state;**

21           **(7) One member from the business community representing businesses on health**  
22 **insurance issues;**

23           **(8) One member from an organization representing the leading research-based**  
24 **pharmaceutical and biotechnology companies;**

25           **(9) One patient advocate;**

26           **(10) One member from the organization representing a majority of hospitals in this**  
27 **state;**

28           **(11) One member from a health carrier as such term is defined under section**  
29 **376.1350;**

30           **(12) One member from the organization representing a majority of health carriers**  
31 **in this state, as such term is defined under section 376.1350;**

32           **(13) One member from the Leukemia and Lymphoma Society; and**

33           **(14) The director of the department of insurance, financial institutions and**  
34 **professional registration, who shall chair the committee.**

35           **3. All members, except for the members from the general assembly, shall be**  
36 **appointed by the governor no later than September 1, 2013. The department of insurance,**  
37 **financial institutions and professional registration shall provide assistance to the**  
38 **committee.**

39           **4. No later than January 1, 2014, the committee shall submit a report to the**  
40 **governor, the speaker of the house of representatives, the president pro tempore of the**  
41 **senate, and the appropriate legislative committee of the general assembly regarding the**  
42 **results of the study and any legislative recommendations.**

✓